Scipher Medicine, a Waltham, Mass.-based developer of a molecular technology platform used to ensure patients are prescribed the most effective therapy, closed a Series B financing.
The amount of the deal was not discloseds.
The round was led by Northpond Ventures, with participation from Alumni Ventures Group and Tachyon Ventures, along with existing investors Khosla Ventures and Granpool Innovative Investments.
Led by Alif Saleh, CEO, Scipher Medicine has developed PrismRATM, a molecular diagnostic test predicting response to anti-tumor necrosis (anti-TNF) therapies, in rheumatoid arthritis patients.
The company identifies, in advance of treatment initiation, if a patient will respond or not so the most optimal drug can be prescribed from day one to improve patient outcomes.